Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798837 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2TACR1GPR119PDE4BMC4R | |
| SCHEMBL3803361 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2TACR1GPR119PDE4BMC4R | |
| SCHEMBL4410764 | 0.92 | MC4R (0.49) | SMN1; SMN2GPR119MC4RMEN1KMT2A | |
| SCHEMBL4414387 | 0.92 | MC4R (0.49) | SMN1; SMN2GPR119MC4RMEN1KMT2A | |
| SCHEMBL4938875 | 0.92 | MC4R (0.49) | SMN1; SMN2GPR119MC4RMEN1KMT2A | |
| SCHEMBL3811657 | 0.90 | TACR1 (0.45) | SMN1; SMN2TACR1GPR119PDE4BMEN1 | |
| SCHEMBL3695315 | 0.90 | GPR119 (0.47) | TACR1GPR119PDE4BMEN1KMT2A | |
| SCHEMBL13493029 | 0.90 | MC4R (0.50) | SMN1; SMN2TACR1PDE4BMC4R | |
| SCHEMBL1267149 | 0.90 | MC4R (0.50) | SMN1; SMN2TACR1PDE4BMC4R | |
| SCHEMBL3968947 | 0.90 | MC4R (0.50) | SMN1; SMN2TACR1PDE4BMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2188266-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021868-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | NR1H2, NR1H3, NR1I2 | SMN1; SMN2 4668/4885TACR1 379/4885GPR119 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.